Merck: priority review for Welireg in US
(CercleFinance.com) - Merck announced Monday that the US FDA has granted priority review to its Welireg tablet for the treatment of advanced pheochromocytomas and paragangliomas.
Pheochromocytomas are adrenal tumors that develop primarily in the adrenal medulla, but can also occur in other cell tissues.
When these tumors are extra-adrenal, they are called paragangliomas.
The 'priority review' designation means that the FDA aims to rule on the approval application within six months, compared with 10 months for a standard review
The FDA's decision is expected on 26 May 2025.
Welireg, which blocks the action of a protein that promotes cancer growth, was already approved in the USA for the treatment of von Hippel-Lindau disease (VHL) and kidney cancer that has spread to other organs.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Pheochromocytomas are adrenal tumors that develop primarily in the adrenal medulla, but can also occur in other cell tissues.
When these tumors are extra-adrenal, they are called paragangliomas.
The 'priority review' designation means that the FDA aims to rule on the approval application within six months, compared with 10 months for a standard review
The FDA's decision is expected on 26 May 2025.
Welireg, which blocks the action of a protein that promotes cancer growth, was already approved in the USA for the treatment of von Hippel-Lindau disease (VHL) and kidney cancer that has spread to other organs.
Copyright (c) 2025 CercleFinance.com. All rights reserved.